Table 1 Characteristics of the study group at the end of the study.
| Age at baseline* (years) | Age at MS onset* (years) | CCA* (mm2) | Individual EDSS Prob (increase)† | Individual MSSS Prob (increase)† | MRI follow‐up* (years) | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Female | 48.6/9.53/26 | 29.9/8.13/26 | −9.21/7.60/25 | 0.65/17/26 | 0.61/6/23 | 9.31/0.83/26 |
| Male | 56.5/10.40/11 | 32.9/8.62/11 | −9.26/4.7/11 | 0.72/8/11 | 0.75/14/8 | 9.09/0.68/11 |
| Interferon | ||||||
| Treatment | 50.7/11.02/24 | 31.3/8.61/24 | −8.44/5.72/23 | 0.79/19/24 | 0.81/17/21 | 9.13/0.80/24 |
| Non‐treatment | 52.1/9.48/13 | 30/7.92/13 | −9.71/5.65/13 | 0.46/6/13 | 0.3/3/10 | 9.46/0.52/13 |
| MS course | ||||||
| RRMS | 47.9/7.54/16 | 31.3/9.21/16 | −8.52/5.84/16 | 0.63/10/16 | 0.60/9/15 | 9.43/0.63/16 |
| SPMS | 52.2/11.81/17 | 29.1/7.18/17 | −10.90/6.42/16 | 0.71/12/17 | 0.62/8/13 | 9.11/0.88/17 |
| PPMS | 60/9.97/4 | 36.3/8.30/4 | −5.61/2.34/4 | 0.75/3/4 | 1.00/3/3 | 9.0/0/4 |
| Overall | 51.2/8.29/37 | 30.8/8.28/37 | −9.25/5.62/36 | 0.67/25/37 | 0.65/20/31 | 9.24/0.72/37 |
CCA, corpus callosum area; EDSS, expanded disability status scale; MS, multiple sclerosis; MSSS, MS severity score; RRMS, relapsing–remitting MS; SPMS, secondary‐progressive MS; PPMS, primary‐progressive MS.
MSSS scale ends at 30 years disease duration—that is, we could monitor only 31 of 37 patients at the end.
*Mean gradient/SD/number of patients.
†Probability/number of patients with increase/number of patients.